• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Pearl Liu

Articles by Pearl Liu

Japan's new regulatory framework speeds regenerative med R&D

March 17, 2016
By Pearl Liu
TOKYO – With a liberalized regulatory environment, Japan is rapidly emerging as a major player in regenerative medicine and is attracting more companies eager to explore the market.
Read More

Fragmented regulatory landscape creates barriers, but Japan’s biopharma push is on

March 16, 2016
By Pearl Liu
TOKYO – Closer collaboration, especially information sharing, between different authorities, universities, clinical institutes as well as companies is called for to speed up biopharmaceutical development in Japan.
Read More

Japan's fragmented regulatory landscape creates barriers

March 16, 2016
By Pearl Liu
TOKYO — Closer collaboration, especially information sharing, between different authorities, universities, clinical institutes as well as companies is called for to speed up biopharmaceutical development in Japan.
Read More

Latest heparin recall stirs made-in-China concerns yet again

March 9, 2016
By Pearl Liu
HONG KONG – In a move that has once again highlighted concerns over the quality of some made-in-China drugs and raw materials, French regulators have raised questions regarding heparin made by a mainland company.
Read More

Latest heparin recall stirs made-in-China concerns yet again

March 9, 2016
By Pearl Liu
HONG KONG – In a move that has once again highlighted concerns over the quality of some made-in-China drugs and raw materials, French regulators have raised questions regarding heparin made by a mainland company.
Read More

Wuxi-manufactured IMP321 becomes first China-made biologic dosed in EU trial

March 9, 2016
By Pearl Liu
HONG KONG – China’s Wuxi Biologics Co. Ltd. managed a breakthrough by getting a biological product it manufactures approved in the use of clinical trials in Belgium, making it the first-ever China-made biologic dosed in a clinical trial in the European Union (EU).
Read More

Chinese regulators increasingly turning their attention to devices

March 4, 2016
By Pearl Liu

Wuxi-manufactured IMP321 becomes first China-made biologic dosed in EU trial

March 4, 2016
By Pearl Liu
HONG KONG – China's Wuxi Biologics Co. Ltd. managed a breakthrough by getting a biological product it manufactures approved in the use of clinical trials in Belgium, making it the first-ever China-made biologic dosed in a clinical trial in the European Union (EU).
Read More

In releasing list of outstanding devices, China is promoting its med-tech sector

March 2, 2016
By Pearl Liu

Sihuan nosedives 54% after hurdling investigation

March 2, 2016
By Pearl Liu
HONG KONG – After an 11-month suspension in trading, shares of Hong Kong-listed Sihuan Pharmaceutical Holdings Group Ltd. (HK:0460) plunged more than 54 percent on Monday.
Read More
Previous 1 2 … 11 12 13 14 15 16 17 18 19 20 21 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • Kidney disease illustration

    Prokidney produces positive phase II CKD data, thunderous stock surge

    BioWorld
    A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel....
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe